<SEC-DOCUMENT>0001209191-20-037744.txt : 20200618
<SEC-HEADER>0001209191-20-037744.hdr.sgml : 20200618
<ACCEPTANCE-DATETIME>20200618212823
ACCESSION NUMBER:		0001209191-20-037744
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200618
FILED AS OF DATE:		20200618
DATE AS OF CHANGE:		20200618

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GADICKE ANSBERT
		CENTRAL INDEX KEY:			0001134655

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39335
		FILM NUMBER:		20974079

	MAIL ADDRESS:	
		STREET 1:		THE JOHN HANCOCK TOWER
		STREET 2:		200 CLARENDON STREET, 54TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Repare Therapeutics Inc.
		CENTRAL INDEX KEY:			0001808158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
		BUSINESS PHONE:		(857) 412-7018

	MAIL ADDRESS:	
		STREET 1:		7210 FREDERICK-BANTING, SUITE 100
		CITY:			ST-LAURENT
		STATE:			A8
		ZIP:			H4S 2A1
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>doc3.xml
<DESCRIPTION>FORM 3 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2020-06-18</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001808158</issuerCik>
        <issuerName>Repare Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>RPTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001134655</rptOwnerCik>
            <rptOwnerName>GADICKE ANSBERT</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O MPM CAPITAL</rptOwnerStreet1>
            <rptOwnerStreet2>450 KENDALL STREET</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Class A Preferred Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.00</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3603161</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Class B Preferred Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.00</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1288948</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F4"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">All series of convertible preferred shares will convert into the number of shares of the Issuer's common stock on a 1-for-1 basis, for
no additional consideration, immediately prior to the closing of the Issuer's initial public offering and have no expiration date.</footnote>
        <footnote id="F2">The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.</footnote>
        <footnote id="F3">The shares are held as follows: 1,636,136 by MPM BioVentures 2014, L.P. (&quot;BV 2014&quot;), 109,128 by MPM BioVentures 2014(B), L.P. (&quot;BV 2014(B)&quot;), 56,317 by MPM Asset Management Investors BV2014 LLC (&quot;AM BV2014&quot;) and 1,801,580 by UBS Oncology Impact Fund L.P. (&quot;UBS Oncology&quot;). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (&quot;BV LLC&quot;) are the direct and indirect general partners of BV 2014 and BV 2014(B). Ansbert Gadicke is a member of BV LLC. MPM Oncology Impact Management GP LLC (&quot;Oncology GP LLC&quot;) is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC.</footnote>
        <footnote id="F4">The shares are held as follows: 864,749 by BV 2014, 57,677 by BV 2014(B), 29,765 by AM BV2014 and 336,757 by UBS Oncology.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Ansbert Gadicke,</signatureName>
        <signatureDate>2020-06-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
